GlassScriptPhysician profile
Pinki K Prasad
NPI 1336296128
$20,179.43
in general payments reported to CMS, 2019-2025
33 companies · $913 in 2025
The $913 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $267 · 2021: $6,854 · 2022: $2,004 · 2023: $4,382 · 2024: $5,172 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,970 · Food and Beverage: $1,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,970.00 |
| Food and Beverage | $1,496.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $10,648.10 | 2019-2024 | Koselugo, Ultomiris |
| Vertex Pharmaceuticals Incorporated | $4,365.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $2,087.74 | 2020-2021 | |
| Novo Nordisk INC | $489.00 | 2019-2025 | Alhemo |
| Novartis Pharmaceuticals Corporation | $318.81 | 2019-2023 | |
| Genetix Biotherapeutics INC | $315.52 | 2023-2025 | Lyfgenia |
| Sobi, INC | $249.48 | 2019-2025 | |
| Servier Pharmaceuticals LLC | $211.40 | 2019-2025 | |
| Csl Behring | $166.06 | 2019-2023 | Idelvion |
| Genzyme Corporation | $145.45 | 2025 | |
| Btg International INC. | $143.91 | 2020-2023 | |
| Incyte Corporation | $124.93 | 2025 | Niktimvo |
| Mesoblast, INC. | $119.90 | 2025 | Ryoncil |
| Bioverativ Therapeutics INC. | $110.26 | 2019 | |
| Octapharma USA, INC. | $103.55 | 2022-2025 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human), Nuwiq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $96.74 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $77.35 | 2019-2022 | |
| Pfizer INC. | $68.67 | 2023-2024 | |
| Seagen INC. | $41.80 | 2023 | Adcetris |
| Bayer Healthcare Pharmaceuticals INC. | $40.55 | 2021-2022 | |
| Eurofins Viracor, LLC | $35.64 | 2021 | |
| Fennec Pharmaceuticals, INC. | $27.91 | 2023 | Pedmark |
| Medunik USA INC. | $25.19 | 2025 | Siklos |
| Epizyme, INC. | $21.31 | 2021 | |
| Grifols USA, LLC | $19.67 | 2019 | |
| Chiesi USA, INC. | $19.48 | 2020 | |
| Rare Disease Therapeutics, INC. | $18.36 | 2019 | |
| Adaptive Biotechnologies Corporation | $18.28 | 2024 | Clonoseq |
| Shire North American Group INC | $16.77 | 2019 | |
| Medexus Pharma, INC. | $15.00 | 2021 | |
| Uswm, LLC | $14.97 | 2025 | Iwilfin |
| Silvergate Pharmaceuticals, INC. | $12.10 | 2019 | |
| Emmaus Medical, INC. | $10.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pinki Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.